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Background: Several cancers show increased levels of lactate dehydrogenase A (LDHA), which are associated with cancer progres-
sion. However, it remains unclear whether LDHA levels are associated with papillary thyroid cancer (PTC) aggressiveness or with 
the presence of the PTC prognostic marker, the BRAFV600E mutation. This study aimed to evaluate the potential of LDHA as a PTC 
prognostic marker.
Methods: LDHA expression was examined in 83 PTC tissue specimens by immunohistochemistry. Human thyroid cell lines were 
genetically manipulated to overexpress BRAFV600E or were treated with a BRAF-specific short hairpin RNA (shBRAF), whose ef-
fects on LDHA expression were evaluated by Western blotting. Data from 465 PTC patients were obtained from The Cancer Ge-
nome Atlas (TCGA) database and analyzed to validate the in vitro results.
Results: LDHA was aberrantly overexpressed in PTC. Intense immunostaining for LDHA was observed in PTC specimens carrying 
mutated BRAF, whereas the intensity was less in wild-type BRAF samples. Overexpression of BRAFV600E resulted in LDHA upreg-
ulation, whereas treatment with shBRAF downregulated LDHA in human thyroid cell lines. Furthermore, LDHA mRNA expression 
was significantly elevated and associated with BRAFV600E expression in thyroid cancer tissues from TCGA database. Additionally, 
LDHA overexpression was found to be correlated with aggressive clinical features of PTC, such as lymph node metastases and ad-
vanced tumor stages.
Conclusion: LDHA overexpression is associated with the BRAFV600E mutation and an aggressive PTC behavior. Therefore, LDHA 
may serve as a biomarker and therapeutic target in PTC.
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INTRODUCTION
Cancer metabolism, which exploits dysregulated metabolic 
pathways, is characterized by increased glycolysis [1]. In nor-
mal cells, adenosine triphosphate is mostly produced by mito-
chondrial oxidative phosphorylation, while cancer cells tend to 
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use glycolysis, despite the presence of oxygen. Named Warburg 
effect, this process relies on lactate dehydrogenase A (LDHA) 
to convert pyruvate to lactate in the final step of glycolysis [2]. 
LDHA is the key enzyme in glycolysis.
Several studies have revealed high expression of LDHA in 
various cancers and its association with cancer progression. In 
esophageal squamous cell carcinoma, LDHA expression is up-
regulated, whereas LDHA knockdown inhibits cell growth and 
migration in vitro and impairs tumorigenesis in vivo [3]. LDHA 
expression is also upregulated in primary clear cell renal carci-
noma, wherein LDHA shows potential utility as a prognostic 
marker [4]. Significantly elevated LDHA has also been ob-
served in patients with gastric cancer, and LDHA expression 
was reported to be correlated with lower overall survival in 
these patients [5].
Thyroid cancer is the most common endocrine malignancy 
[6]. The rising incidence of thyroid cancer, especially papillary 
thyroid cancer (PTC), is a worldwide phenomenon [7,8]. The 
BRAFV600E mutation, which is the most common driver muta-
tion in PTC, is known to have aggressive features, such as ex-
trathyroidal extension, lymph node metastasis, and an advanced 
cancer stage [9-11]. However, the BRAFV600E mutation is not an 
independent predictor of PTC, and novel prognostic markers 
are needed. Recently, some progress has been achieved regard-
ing thyroid tumor metabolism [12]. Previous studies have dem-
onstrated that the expression of glycolytic enzymes is upregu-
lated in thyroid cancer [13,14]. However, it is not entirely clear 
whether LDHA levels are associated with the aggressiveness of 
PTC or the presence of BRAFV600E mutation [15]. Considering 
the pivotal role of LDHA in the regulation of metabolic path-
ways, its implication in the metabolic switch of PTC warrants 
further investigation.
This study aimed to evaluate the potential of LDHA as a 




Human thyroid cancer tissue samples (n=83) and matched con-
tralateral normal tissue samples (n=81), who underwent thy-
roidectomy for PTC between October 2005 and April 2014 at 
the Yonsei University Severance Hospital (Seoul, Korea), were 
obtained. We included patients whose preoperative 2-deoxy-
2-[18F]fluoro-D-glucose (FDG) positron emission tomography 
integrated with computed tomography imaging and BRAFV600E 
mutation results were available. Patients who had a history of 
other cancers or autoimmune thyroiditis (proven by the pres-
ence of elevated levels of thyroid antibodies and by thyroid im-
aging) were excluded. All samples were obtained as formalin-
fixed paraffin-embedded tissue blocks. This study was conduct-
ed in accordance with the Declaration of Helsinki and was ap-
proved by the Institutional Review Board of the Severance Hos-
pital (No. 4-2015-0677). Written informed consent was obtained 
from all patients included in the study.
Data from The Cancer Genome Atlas thyroid cancer 
database
Publicly available mRNA sequencing (RNA-Seq) data, somatic 
mutation data, and clinical information of 465 patients with thy-
roid cancer from The Cancer Genome Atlas (TCGA) database 
(version 2016_01_28; https://gdac.broadinstitute.org) were ana-
lyzed [16,17]. The overall survival, disease-free survival, dis-
ease-specific survival, and progression-free survival data were 
downloaded from cBioPortal (TCGA, Firehose Legacy, and 
PanCancer Atlas). All the collected data were fully anonymized 
before we accessed the patient information. Patients with a his-
tory of any other malignancy and those without BRAF or 
LDHA information were not included in the study. Thyroid can-
cer staging was based on the 7th edition of the American Joint 
Committee on Cancer (AJCC) cancer staging system.
Cell culture
Three human thyroid cell lines (Nthy-ori 3-1, SNU-790, and 
8505C) were used for in vitro experiments. Nthy-ori 3-1 cells 
were provided by Dr. Seongho Ryu (Soonchunhyang Universi-
ty, Cheonan, Korea), and 8505C cells were provided by Dr. 
Seong Jin Lee (Hallym University, Chuncheon, Korea). SNU-
790 cells were purchased from the Korean Cell Line Bank 
(KCLB No. 00790.1, Seoul, Korea). All the cell lines were au-
thenticated by short tandem repeat profiling and confirmed to 
be free of Mycoplasma contamination. Cells were cultured in 
RPMI-1640 medium (Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA), supplemented with 10% fetal bovine se-
rum (HyClone, Logan, UT, USA) and 1% penicillin/streptomy-
cin, in a humidified atmosphere of 5% CO2 and 95% air at 
37°C.
Transfection
pCDH-B-Raf and pCDH-B-RafV600E vectors were kindly 
provided by Tae Jun Park [18]. Lentiviral particles were gener-
ated using three plasmids, VSVG, RSV-REV, and PMDLg/
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pPRE, cotransfected with the pCDH-B-Raf or pCDH-B-
RafV600E plasmid in HEK293FT cells (R70007, Invitrogen, 
Carlsbad, CA, USA) using the Lipofectamine 2000 transfection 
reagent (#11668019, Invitrogen). Two days after the transfec-
tion, the culture medium was collected and passed through a 
0.45-μm filter. The purified lentiviral particles were used to in-
fect Nthy-ori 3-1 cells.
The BRAF-specific short hairpin RNA (shRNA) and a scram-
bled negative control were purchased from OriGene (Rockville, 
MD, USA). Cells were seeded onto 6-well plates and transfect-
ed with the shRNA using Lipofectamine 2000 (Invitrogen). The 
shRNA-transfected cells were subjected to Western blot analy-
sis 72 hours after transfection.
Western blot analysis
Western blot analysis was performed as previously described in 
a study [19]. Membranes were immunoassayed with antibodies 
specific to the following antigens: LDHA (1:1,000; 3582S), ex-
tracellular signal-regulated kinase 1/2 (ERK1/2; 1:1,000; 
9102S), phosphorylated ERK1/2 (pERK1/2; 1:1,000; 9106S, 
Cell Signaling Technology, Danvers, MA, USA), β-actin 
(1:5,000; A1978, Sigma-Aldrich, St. Louis, MO, USA), and 
BRAF (1:1,000; sc-5284, Santa Cruz Biotechnology, Dallas, 
TX, USA). The secondary antibodies included horseradish per-
oxidase-conjugated goat anti-rabbit immunoglobulin G (IgG; 
1:5,000; 31460) and goat anti-mouse IgG (1:5,000; 31430, 
Thermo Fisher Scientific). Signals were visualized using Amer-
sham ECL Western blotting detection reagents (GE Healthcare 
Life Sciences, Chicago, IL, USA).
Immunohistochemistry 
Paraffin-embedded tissue specimens were cut into 4-μm-thick 
sections, and immunohistochemistry (IHC) staining was per-
formed using a Discovery XT autoimmunostainer (750-701, 
Ventana, Tucson, AZ, USA) with monoclonal antibodies against 
glucose transporter 1 (GLUT1; 1:100; sc-377228, Santa Cruz 
Biotechnology), pyruvate kinase isoform M2 (PKM2; 1:500; 
4053S), and LDHA (1:100; 3582S, Cell Signaling Technology), 
according to the manufacturer’s instructions.
The IHC results were assessed by two experts using immuno-
reactive scoring by multiplying the intensity of staining (I) (0–3 
points: absent, weak, intermediate, and strong, respectively) 
with the percentage of positive tumor cells (P) (0–4 points: 0%, 
1%–24%, 25%–49%, 50%–74%, and 75%–100%, respective-
ly). The final calculated immunoreactive score (H=P×I) was 
evaluated according to the following scale: low (0–4 points), 
moderate (6–8 points), and high (9–12 points).
Statistical analysis
IBM SPSS Statistics version 25 (IBM, Armonk, NY, USA) was 
used for all statistical analyses. Categorical variables are pre-
sented as the number and percentage, and continuous variables 
are presented as the mean±standard deviation. Statistical com-
parisons of mean values were performed using Student’s t test 
for two groups and analysis of variance for more than two 
groups. As an exception, the Mann-Whitney U test and Kruskal-
Wallis test were used to compare the mRNA expression results, 
as they usually do not present a normal distribution. Group 
comparisons were performed using the chi-square test or a lin-
ear-by-linear association test, as appropriate. Survival analyses 
were performed using Gehan’s generalized Wilcoxon method. 
Univariate and multivariate analyses were used to determine the 
variables independently associated with lymph node metastasis. 
Odds ratios and 95% confidence intervals were determined. 
Differences with a P value <0.05 were considered statistically 
significant.
RESULTS
Expression of glycolytic enzymes in human thyroid cancer 
tissues
To evaluate whether glycolysis is increased in PTC, the levels 
of important glycolytic enzymes, such as GLUT1, PKM2, and 
LDHA were compared among 83 cancer specimens and 81 
matched normal specimens from the same patients by immuno-
histochemical staining (Fig. 1). Basal characteristics of 83 pa-
tients included in the study are shown in Supplemental Table 
S1. GLUT1, PKM2, and LDHA levels were significantly up-
regulated in the thyroid cancer tissues compared with their nor-
mal counterparts (P<0.001) (Table 1).
Next, glycolytic enzyme levels were compared according to 
the BRAFV600E mutational status. Of the 83 patients with thyroid 
cancer, 71 (85.5%) had PTC-positive BRAFV600E mutation, and 
12 (14.5%) had wild-type (WT) BRAF. GLUT1 and PKM2 lev-
els were similar between the BRAFV600E and WT BRAF groups, 
whereas LDHA level was significantly higher in the BRAFV600E 
group (P=0.020) (Table 2). These results demonstrate a clear 
association between the levels of LDHA and the presence of the 
BRAFV600E mutation in patients with PTC.
LDHA expression in human thyroid cell lines
To investigate whether the presence of the BRAFV600E mutation 
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leads to the upregulation of LDHA expression in thyroid cancer, 
LDHA level was analyzed in BRAF-overexpressing thyroid 
cells. BRAFV600E-overexpressing Nthy-ori 3-1 cells had a spin-
dle-transformed shape that may be the result of epithelial-mes-
enchymal transition induced by the BRAFV600E mutation (Fig. 
2A). BRAFV600E-overexpressing Nthy-ori 3-1 cells showed sig-
nificantly higher levels of pERK than WT BRAF-overexpress-
ing cells (Fig. 2B), as well as high levels of LDHA. Thus, over-
expression of BRAFV600E in vitro activated the mitogen-activat-
ed protein kinase signaling pathway, thereby promoting LDHA 
expression.
Next, the effects of BRAF inhibition on LDHA expression 
were investigated in the human thyroid cell lines. BRAF knock-
down experiments were performed in SNU-790 and 8505c cells 
using a BRAF-specific shRNA (shBRAF). BRAF inhibition led 
to a reduced expression of LDHA in these cell lines (Fig. 3). 
These results suggest that the presence of the BRAFV600E muta-
tion may lead to the upregulation of LDHA expression through 
the BRAF/mitogen-activated protein kinase signaling pathway 
in thyroid cancer.
TCGA thyroid cancer data according to the LDHA mRNA 
expression status
To confirm our findings on LDHA expression patterns in PTC 
and evaluate whether LDHA expression is associated with the 
aggressiveness of PTC, as well as with the presence of the 
BRAFV600E mutation, data obtained from TCGA thyroid cancer 
database were evaluated. First, mRNA levels of GLUT1, PKM2, 
Table 1. Glycolytic Enzyme Level in Normal Thyroid and Pap-






   Low 80 (98.8) 8 (9.6)
   Moderate 1 (1.2) 71 (85.5)
   High 0 4 (4.8)
PKM2 expression <0.001
   Low   79 (97.5) 2 (2.4)
   Moderate 2 (2.5) 22 (26.5)
   High 0 59 (71.1)
LDHA expression <0.001
   Low 80 (98.8) 6 (7.2)
   Moderate 1 (1.2) 21 (25.3)
   High 0 56 (67.5)
Values are expressed as number (%).
GLUT1, glucose transporter 1; PKM2, pyruvate kinase isoform M2; 
LDHA, lactate dehydrogenase A.
Table 2. Association between Glycolytic Enzyme Level and the 
BRAFV600E Mutation





   Low 1 (8.3) 7 (9.9)
   Moderate 10 (83.3) 61 (85.9)
   High 1 (8.3) 3 (4.2)
PKM2 expression 0.145
   Low 0 2 (2.8)
   Moderate 6 (50.0) 16 (22.5)
   High 6 (50.0) 53 (74.6)
LDHA expression 0.020
   Low 3 (25.0) 3 (4.2)
   Moderate 4 (33.3) 17 (23.9)
   High 5 (41.7) 51 (71.8)
Values are expressed as number (%).
WT, wild-type; GLUT1, glucose transporter 1; PKM2, pyruvate kinase 
isoform M2; LDHA, lactate dehydrogenase A.
Fig. 1. Lactate dehydrogenase A (LDHA) expression in normal and tumor tissues analyzed by immunohistochemistry. (A) Normal thyroid 
tissue; (B) weakly, (C) intermediately, and (D) strongly stained papillary thyroid carcinoma tissues (×400). 
A B C D
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and LDHA were examined, revealing that GLUT1 and PKM2 
expression was significantly elevated in thyroid cancer tissues 
compared with normal tissues (P<0.001) (Fig. 4A, B). LDHA 
mRNA levels were also significantly higher in thyroid cancer 
tissues (P=0.016) (Fig. 4C). The mRNA levels of GLUT1, 
PKM2, and LDHA in paired PTC tissues and normal tissues 
were also examined and shown in Supplemental Fig. S1. These 
findings were consistent with the previous IHC results.
Next, the patients with PTC were divided into three groups 
based on the LDHA expression: low (n=155), moderate 
(n=155), and high (n=155) expression groups (Table 3).
The analysis of the clinicopathological characteristics of the 


















Fig. 2. Protein expression in Nthy-ori 3-1 cells stably expressing 
the wild-type (WT) BRAF or BRAF with the V600E mutation. (A) 
Photomicrographs of BRAFV600E- and WT BRAF-overexpressing 
cells. (B) BRAF, extracellular signal-regulated kinase (ERK), phos-
phorylated ERK (pERK), lactate dehydrogenase A (LDHA), and 
β-actin levels in BRAFV600E- and WT BRAF-overexpressing cells. 
The blot is representative of three independent experiments.
Fig. 3. Lactate dehydrogenase A (LDHA) expression in human thy-
roid cell lines after BRAF-specific short hairpin RNA (shBRAF) 
treatment. (A) SNU-790 and (B) 8505c cells. Each blot is represen-



















































Fig. 4. mRNA expression of glycolytic enzyme-encoding genes 
based on The Cancer Genome Atlas thyroid cancer database. (A) 
Glucose transporter 1 (GLUT1), (B) pyruvate kinase isoform M2 
(PKM2), and (C) lactate dehydrogenase A (LDHA) expression lev-
els in 465 papillary thyroid carcinoma and 55 normal thyroid tis-
sues. Data are presented as the individual value, median, and inter-
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Low (n=155) Moderate (n=155) High (n=155)
Age, yr 46.85±15.73 45.97±15.39 46.81±15.65 0.855
Sex 0.300
   Male 37 (23.9) 38 (24.5) 45 (29.0)
   Female 118 (76.1) 117 (75.5) 110 (71.0)
Tumor size, cm 2.96±1.71 2.69±1.55 3.06±1.61 0.145
Extrathyroidal extension <0.001
   Negative 126 (81.3) 110 (71.0) 78 (50.3)
   Minimal 25 (16.1) 38 (24.5) 58 (37.4)
   Moderate/advanced 1 (0.6) 2 (1.3) 13 (8.4)
   Unknown 3 (1.9) 5 (3.2) 6 (3.9)
Multifocality 0.294
   Negative 78 (50.3) 86 (55.5) 86 (55.5)
   Positive 72 (46.5) 67 (43.2) 66 (42.6)
   Unknown 5 (3.2) 2 (1.3) 3 (1.9)
T stage 0.001
   T1 46 (29.7) 52 (33.5) 34 (21.9)
   T2 58 (37.4) 56 (36.1) 42 (27.1)
   T3 49 (31.6) 42 (27.1) 66 (42.6)
   T4 2 (1.3) 4 (2.6) 13 (8.4)
   Tx 0 1 (0.6) 0 
N stage 0.039
   N0 92 (59.4) 66 (42.6) 54 (34.8)
   N1a 30 (19.4) 48 (31.0) 60 (38.7)
   N1b 13 (8.4) 26 (16.8) 31 (20.0)
   Nx 20 (12.9) 15 (9.7) 10 (6.5)
Distant metastasis 0.050
   M0 75 (48.4) 87 (56.5) 92 (59.4)
   M1 2 (1.3) 3 (1.9) 2 (1.3)
   Mx 78 (50.3) 64 (41.6) 61 (39.4)
TNM stage 0.001
   I 95 (61.3) 98 (64.1) 81 (52.3)
   II 24 (15.5) 12 (7.8) 8 (5.2)
   III 28 (18.1) 23 (15.0) 39 (25.2)
   IV 8 (5.2) 20 (13.1) 27 (17.4)
BRAF mutation <0.001
   WT 119 (76.8) 74 (47.7) 55 (35.5)
   V600E 36 (23.2) 81 (52.3) 100 (64.5)
   TDS 0.55±0.96 −0.05±0.94 −0.46±0.87 <0.001
Values are expressed as mean±standard deviation or number (%).
LDHA, lactate dehydrogenase A; TNM, tumor, node, metastasis; WT, wild-type; TDS, thyroid differentiation score.
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Table 4. Data of Univariate and Multivariate Analyses of Lymph Node Metastasis in Patients with Papillary Thyroid Cancer
Variable
Univariate analysis Multivariate analysisa
OR 95% CI P value OR 95% CI P value
Age 0.987 0.976–0.999 0.038
Female sex 0.599 0.394–0.910 0.016 0.735 0.461–1.174 0.198
Multifocality 1.461 1.007–2.120 0.046 1.602 1.057–2.428 0.026
Extrathyroidal extension
   Negative - - - - - -
   Minimal 2.596 1.688–3.992 <0.001 1.516 0.797–2.882 0.205
   Moderate/advanced 11.948 2.668–53.506 0.001 4.080 0.381–43.719 0.245
Tumor size, cm 1.198 1.062–1.351 0.003
T stage
   T1 - - - - - -
   T2 1.600 0.981–2.610 0.060 1.705 1.006–2.890 0.048
   T3 2.933 1.803–4.774 <0.001 2.121 1.074–4.188 0.030
   T4 12.267 3.384–44.463 <0.001 3.398 0.407–28.396 0.259
LDHA expression
   Low - - - - - -
   Moderate 2.380 1.484–3.816 0.001 2.540 1.507–4.283 <0.001
   High 3.703 2.303–5.957 <0.001 2.920 1.685–5.059 <0.001
BRAFV600E mutation 1.466 1.015–2.118 0.041 0.962 0.623–1.484 0.861
OR, odds ratio; CI, confidence interval; T stage, tumor stage; LDHA, lactate dehydrogenase A.
aMultivariate models were adjusted for gender, multifocality, extrathyroidal extension, T stage, LDHA mRNA expression, and BRAFV600E mutation using 
the Enter method.
with extrathyroidal extension, T stage, N stage, TNM stage, and 
BRAFV600E mutation, but not with other parameters, such as age 
and sex. The thyroid differentiation score was negatively associ-
ated with high LDHA levels. Moreover, univariate and multi-
variate analyses confirmed that high LDHA expression was as-
sociated with lymph node metastases (Table 4). These data indi-
cate that high expression of LDHA may be used as a biomarker 







































Fig. 5. Lactate dehydrogenase A (LDHA) gene expression levels according to the BRAFV600E mutational status or papillary thyroid cancer 
(PTC) subtype, based on The Cancer Genome Atlas (TCGA) thyroid cancer database. (A) LDHA mRNA expression levels in BRAF wild-
type (WT) and V600E mutant PTC. (B) LDHA mRNA expression levels according to the subtype of PTC. Data are presented as the individ-
ual value, median, and interquartile range. RSEM, RNA-Seq by expectation-maximization. aClassic, classical/usual; bFV, follicular (≥99% 
follicular patterned); cTV, tall-cell (≥50% tall cell features); dOther, uncommon PTC variants.
A B
P<0.001 P<0.001
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survival curves of groups with different levels of LDHA expres-
sion. The overall survival, disease-free survival, disease-specific 
survival, and progression-free survival did not differ between 
the three groups (P=0.651, P=0.244, P=0.582, and P=0.290, 
respectively) (Supplemental Fig. S2). The mean survival rate 
after 10 years was higher than 90%.
To further confirm the IHC findings regarding LDHA expres-
sion patterns with respect to the BRAFV600E mutational status, 
the latter two parameters were compared in the patient data from 
TCGA database. LDHA expression was enhanced in patients 
with PTC who harbored the BRAFV600E mutation compared with 
those who had the WT gene (P<0.001) (Fig. 5A). Analysis of 
LDHA expression in light of PTC subtypes, namely classical/
usual, follicular, tall-cell, and other uncommon PTC variants, 
revealed significantly higher LDHA level within the classical 
type than in the follicular variant type (P<0.001) (Fig. 5B), as 
well as in the tall-cell variant type than in the classical type 
(P<0.001). Taken together, these results indicate that LDHA 
overexpression is associated with the aggressiveness of PTC, as 
well as with the presence of the BRAFV600E mutation.
DISCUSSION
Although partly attributed to overdiagnosis, the incidence of 
thyroid cancer, particularly PTC, has increased in recent years 
worldwide [7,8]. Nevertheless, a decreasing trend has been re-
ported in thyroid cancer mortality [6]. Therefore, risk stratifica-
tion and tailored management, along with the identification of 
novel prognostic markers, are crucial, yet unmet clinical goals 
in thyroid cancer management [20-22]. Herein, we showed that 
LDHA, a key glycolytic enzyme, could be used as a potential 
prognostic marker in thyroid cancer.
We demonstrated that the levels of glycolytic enzymes, in-
cluding LDHA, were significantly upregulated in PTC. These 
observations were further confirmed by the examination of the 
LDHA expression in a set of 465 cases of PTC from TCGA thy-
roid cancer database. Thus, similar to previous reports [13,14], 
the present study also revealed higher levels of GLUT1, PKM2, 
and LDHA in PTC compared with normal tissues.
These dysregulated metabolic enzymes are the basis of cancer 
cell metabolic reprogramming. Abnormal overexpression of 
LDHA in several cancers is attributed to the activation of its up-
stream pathway by cancer-driving mutations [1]. A previous 
study demonstrated that the HIF1α–MYC–PGC-1β axis is al-
tered by the BRAFV600E mutation, resulting in the inhibition of 
mitochondrial respiration and the enhancement of aerobic gly-
colysis. Moreover, LDHA and PKM2 are elevated in thyroid 
cancer samples with the BRAFV600E mutation [15]. Therefore, 
the levels of glycolytic enzymes in patients with PTC according 
to their BRAFV600E mutational status, which is the most com-
mon mutation found in thyroid cancer, were also evaluated. 
Contrary to results in previous studies [15,23], only LDHA ex-
pression was significantly higher in the BRAFV600E mutation 
group compared with that in the WT BRAF group. It might be 
due the different regulatory mechanism of each enzyme or sam-
pling criteria [24]. LDHA is considered as a key checkpoint of 
anaerobic glycolysis. The relationship between the expression 
of LDHA and the presence of the BRAFV600E mutation was also 
supported by TCGA mRNA data.
To elucidate the role of LDHA in thyroid cancer, further anal-
ysis of the relationship between aberrant LDHA expression and 
the presence of the BRAFV600E mutation was performed. LDHA 
levels were found to be significantly higher in BRAFV600E- than 
in WT BRAF-overexpressing thyroid cells. These cell line pairs 
are recognized as a suitable model to study the molecular altera-
tions induced by the BRAFV600E mutation [25]. To the best of our 
knowledge, this study is the first to report that the BRAFV600E 
mutant protein causes LDHA overexpression in human thyroid 
cell lines. We validated this finding using a shBRAF in two hu-
man thyroid cell lines, showing that the BRAFV600E mutation 
plays a significant role in the regulation of LDHA expression in 
vitro. Notably, these findings are consistent with a recent report 
suggesting that BRAFV600E-mediated metabolic reprogramming 
increases glycolytic metabolism, which may mediate the War-
burg effect [15]. However, we could not reveal the exact mecha-
nism by which the BRAFV600E mutation regulated the expression 
of LDHA in this study. This is a limitation of our study.
It was also demonstrated that high levels of LDHA correlate 
with aggressive clinical features of PTC, such as extrathyroidal 
extension, lymph node metastasis, and an advanced cancer 
stage. These aggressive features are related to the recurrence of 
PTC, poor response to treatment, and lower overall patient sur-
vival [26]. However, our survival analyses showed no differ-
ences between groups with different LDHA expression levels. 
This may be because most thyroid cancers grow slowly and are 
associated with a very favorable prognosis [21]. Univariate and 
multivariate analyses revealed that LDHA levels are an inde-
pendent prognostic marker of lymph node metastasis in PTC. 
Furthermore, the data suggested that the BRAFV600E mutation 
may lead to tumor aggressiveness by altering the expression 
levels of glycolytic enzymes, such as LDHA. As indicated by 
recent studies, elevated LDHA levels promote the progression 
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of malignant tumors by modulating lactic acid production, gly-
colysis, reactive oxygen species production, and the expression 
of numerous cancer-related proteins [1]. To the best of our 
knowledge, this is also the first study to evaluate and stratify 
clinicopathological characteristics of thyroid cancer according 
to the levels of LDHA expression.
[18F]-FDG positron emission tomography integrated with 
computed tomography imaging is widely used in the diagnosis 
and prognostic evaluation of tumors. In particular, the [18F]-FDG 
uptake seems to be an indicator of poorly differentiated and 
highly malignant thyroid cancer [27]. Marked reduction in glu-
cose consumption in LDHA-silenced cells may be accompanied 
by concurrent decrease in FDG uptake, suggesting a possible 
association between the FDG uptake and LDHA expression [24, 
28]. It was also suggested that the presence of the BRAFV600E 
mutation is associated with the [18F]-FDG uptake and GLUT1 
expression rates in PTC [29]. The relationship between LDHA 
levels and [18F]-FDG uptake was also analyzed but no relevant 
associations were identified (Supplemental Table S2). Possible 
reasons for this discordance include (1) [18F]-FDG uptake may 
not necessarily correlate with lactate production, because the 
upregulation of the pentose phosphate shunt may also result in 
increased glucose consumption; (2) glucose transporter activity 
is the major rate-limiting step of [18F]-FDG uptake in some tu-
mors; and (3) very high incidence of BRAFV600E mutation may 
have made it difficult to evaluate the relationship [28]. Howev-
er, further research is still needed.
In summary, this study demonstrated that LDHA overexpres-
sion is correlated with aggressive clinical features of PTC. In 
particular, LDHA could serve as an independent prognostic 
marker of lymph node metastasis, and LDHA overexpression is 
associated with the presence of the BRAFV600E mutation in PTC. 
At present, the most widely accepted prognostic markers for 
thyroid cancer are the BRAFV600E mutation and mutations in the 
human telomerase reverse transcriptase promoter [30,31]. How-
ever, there is a clear need for novel prognostic markers [7]. The 
integration of LDHA expression with these well-established 
markers may help accurately predict poor prognosis in patients 
with thyroid cancer. To improve our current understanding of 
thyroid cancer, as well as its management and treatment, more 
in-depth insights into the role of LDHA are warranted.
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